Health Law & Business News

Gilead Can Challenge University’s Virus Treatment Patent

May 29, 2020, 9:45 PM

The Patent Trial and Appeal Board has granted Gilead’s request to review the validity of a patent owned by the University of Minnesota for compounds used to treat viral infections.

  • PTAB said that Gilead has “satisfied the threshold requirement” of showing it has a reasonable likelihood of winning the argument that the patent is invalid
  • The university’s patent 8,815,830, titled “Nucleosides with Antiviral and Anticancer Activity,” covers “an enormous number of compounds,” Gilead contends
  • Gilead said those compounds include sofosbuvir, the active ingredient in its HepC treatments that was already known before the school’s patent application was officially filed and...

To read the full article log in. To learn more about a subscription click here.